President Trump’s Food and Drug Administration may not be as lax as the drug industry hoped. The agency rejected a debatably effective treatment for muscular dystrophy Wednesday, signaling that its self-professed openness to approving new drugs has limitations.

The drug, developed by PTC Therapeutics (PTCT), was meant to treat the rare disease Duchenne muscular dystrophy, but failed to differentiate itself from placebo in two clinical trials.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy